Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Item
http://www.wikidata.org/entity/Q38756800
Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.Drug Repurposing for the Treatment of Acute Myeloid Leukemia.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.TRIM proteins in blood cancers.Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice.Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis
P2860

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Item
http://www.wikidata.org/entity/Q38756800
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Modern multiple myeloma therap ...... se and good clinical outcomes.
@en
type
label
Modern multiple myeloma therap ...... se and good clinical outcomes.
@en
prefLabel
Modern multiple myeloma therap ...... se and good clinical outcomes.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Modern multiple myeloma therap ...... se and good clinical outcomes.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698